Salani R, McCormack M, Kim YM, Ghamande S, et al. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer 2024;34:1140-1148.
PMID: 40228934